[2-(5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene-2-ylmethoxy)-ethyl]-dimethylamine | 629642-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: [2-(5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene-2-ylmethoxy)-ethyl]-dimethylamine
• 英文别名: 2-[(9-chloro-13-oxa-3-thia-5-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),2(6),4,7(12),8,10,14,16-octaen-4-yl)methoxy]-N,N-dimethylethanamine
• CAS: 629642-63-3
• 化学式: C₂₀H₁₉ClN₂O₂S
• 分子量: 386.902
• InChiKey: OAHMBFKSFPVRDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• USE OF 1-THIA-DIBENZO E,H AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
  申请人：PLIVA-ISTRAZIVACKI INSTITUT d.o.o.

  公开号：EP1684751A1

  公开（公告）日：2006-08-02
• 1-Thia-3-aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
  申请人：Mercep Mladen

  公开号：US20070078123A1

  公开（公告）日：2007-04-05

  The present invention relates to the use of derivatives from the group of 1-thia-3-aza-dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates in a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.
• [EN] USE OF 1-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS<br/>[FR] UTILISATION DE 1-THIA-DIBENZO[E,H]AZULENES POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT ET A LA PREVENTION DES MALADIES ET DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：PLIVA ISTRAZIVACKI INST D O O

  公开号：WO2005049020A1

  公开（公告）日：2005-06-02

  The present invention relates to the use of derivatives from the group of 1-thia-3-aza­dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates for the manufacture of a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.